Northern Trust Corp Acquires 634,045 Shares of InflaRx (NASDAQ:IFRX)

Northern Trust Corp boosted its holdings in shares of InflaRx (NASDAQ:IFRX - Free Report) by 1,933.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 666,845 shares of the company's stock after buying an additional 634,045 shares during the quarter. Northern Trust Corp owned approximately 1.13% of InflaRx worth $1,647,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of IFRX. Two Sigma Securities LLC acquired a new position in InflaRx during the fourth quarter worth approximately $28,000. Walleye Capital LLC acquired a new position in shares of InflaRx in the fourth quarter valued at approximately $51,000. Geode Capital Management LLC grew its position in shares of InflaRx by 32.8% in the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock valued at $119,000 after purchasing an additional 11,900 shares during the last quarter. Commonwealth Equity Services LLC grew its position in shares of InflaRx by 20.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company's stock valued at $275,000 after purchasing an additional 19,000 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of InflaRx in the fourth quarter valued at approximately $1,576,000. Institutional investors and hedge funds own 42.39% of the company's stock.

InflaRx Stock Performance

Shares of IFRX stock traded down $1.09 during trading on Wednesday, hitting $0.73. The company had a trading volume of 7,974,719 shares, compared to its average volume of 260,286. The firm has a market capitalization of $49.04 million, a P/E ratio of -0.68 and a beta of 1.57. The stock's 50-day moving average price is $1.35 and its 200 day moving average price is $1.83. InflaRx has a one year low of $0.71 and a one year high of $2.82.

InflaRx (NASDAQ:IFRX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.04. The business had revenue of $0.03 million during the quarter, compared to analysts' expectations of $0.03 million. InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%. On average, research analysts anticipate that InflaRx will post -1.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on IFRX shares. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 target price on shares of InflaRx in a research report on Friday, March 21st. Cantor Fitzgerald started coverage on InflaRx in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 target price on the stock. Oppenheimer started coverage on InflaRx in a research report on Thursday, May 8th. They issued an "outperform" rating and a $6.00 target price on the stock. Finally, Guggenheim upped their target price on InflaRx from $7.00 to $10.00 and gave the company a "buy" rating in a research report on Wednesday, March 26th.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.